While the availability of vaccines efficiently protects individuals from infection with influenza virus, there is still a great need for specific antiviral drugs that prevent disease progression and virus transmission. This will be particularly important during either an epidemic or pandemic outbreak where prior vaccination is unlikely to confer protection, therefore increasing the susceptible population. It is also advantageous to have at least two antiviral drugs (aimed at different targets) available due to the rapid emergence of resistant virus strains. Of the two current classes of FDA-approved influenza virus antiviral drugs, only the neuraminidase inhibitors remain effective against current circulating viruses, so the time has come to develop new and improved antiviral drugs against influenza virus. Unlike our predecessors, we have the advantage of working in the post-genomic era and this affords us the ability to expand the number of potential drug targets to include those host proteins that the virus needs to complete its replication cycle.
Our first aim i n this proposal is to identify these cellular requirements through the use of RNA interference technology. In addition to identifying requirements of essential replication pathways, we will also strive to find host factors involved in virus pathogenesis, which ultimately determines disease severity. For this purpose we will focus on the anti-interferon properties of the influenza NS1 protein which is a proven determinant of virulence.
In specific aim 2 we will select the lead host factors for use as targets in biochemical assays to detect small molecules with specific inhibitory activity against these proteins. We hypothesize that these compounds will also have anti-influenza virus activity and in fact may have an advantage over drugs that target viral proteins, as resistance is less likely to develop. To further identify candidate antiviral drugs, we will also conduct a screen to identify small molecule inhibitors of influenza virus growth in a cell-based assay. The challenge of identifying the targets of these compounds will most likely favor the selection of inhibitors of viral proteins but with the benefit that their efficacy in vivo is part of the selection criteria. Therefore, using two distinct approaches we aim to identify influenza virus specific antiviral compounds that target both viral and host requirements for influenza virus growth and to initiate pre-clinical evaluation of the lead compounds.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI074539-05
Application #
8098086
Study Section
Special Emphasis Panel (ZAI1-CCH-M (M2))
Program Officer
Krafft, Amy
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
5
Fiscal Year
2011
Total Cost
$1,427,583
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
White, Kris M; De Jesus, Paul; Chen, Zhong et al. (2015) A Potent Anti-influenza Compound Blocks Fusion through Stabilization of the Prefusion Conformation of the Hemagglutinin Protein. ACS Infect Dis 1:98-109
Bhattacharyya, Suchita; Zagórska, Anna; Lew, Erin D et al. (2013) Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe 14:136-47
Mata, Miguel A; Satterly, Neal; Versteeg, Gijs A et al. (2011) Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor. Nat Chem Biol 7:712-9
Bortz, Eric; Westera, Liset; Maamary, Jad et al. (2011) Host- and strain-specific regulation of influenza virus polymerase activity by interacting cellular proteins. MBio 2:
Shaw, Megan L (2011) The host interactome of influenza virus presents new potential targets for antiviral drugs. Rev Med Virol 21:358-69
König, Renate; Stertz, Silke; Zhou, Yingyao et al. (2010) Human host factors required for influenza virus replication. Nature 463:813-7
Versteeg, Gijs A; García-Sastre, Adolfo (2010) Viral tricks to grid-lock the type I interferon system. Curr Opin Microbiol 13:508-16
Schmolke, Mirco; García-Sastre, Adolfo (2010) Evasion of innate and adaptive immune responses by influenza A virus. Cell Microbiol 12:873-80
Widjaja, Ivy; de Vries, Erik; Tscherne, Donna M et al. (2010) Inhibition of the ubiquitin-proteasome system affects influenza A virus infection at a postfusion step. J Virol 84:9625-31
Wang, Taia T; Palese, Peter (2009) Universal epitopes of influenza virus hemagglutinins? Nat Struct Mol Biol 16:233-4

Showing the most recent 10 out of 12 publications